Skip to main content

Table 1 General characteristics of male and female T2DM patients and non-diabetic subjects

From: Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients

Gender/characteristic

Female

Male

Non-diabetic

T2DM

Non-diabetic

T2DM

Number of females

149

150

149

150

N in category, (%)

 Hypertension

47 (31.5 %)

63 (42.0 %)

36 (24.5 %)

69 (46.0 %)ł

 Cardiovascular disease

6 (4.0 %)

14 (9.3 %)

8 (5.4 %)

22 (14.7 %)ł

 Anti-hypertensive Medications

  Diuretics

2 (1.3 %)

2 (1.3 %)

2 (1.3 %)

7 (4.7 %)

  β blocker

4 (2.7 %)

12 (8.0 %)*

3 (2.0 %)

7 (4.7 %)

  Calcium channel blocker

7 (4.7 %)

24 (16.0 %)

9 (6.0 %)

32 (21.3 %)ǂ

  α blocker

4 (2.7 %)

11 (7.3 %)

0 (0 %)

17 (11.3 %)§

  ACE inhibitors/ARB

3 (2.0 %)

7 (4.7 %)

2 (1.3 %)

14 (9.3 %)ǂ

 Lipid lowering treatment

4 (2.7 %)

2 (1.3 %)

4 (2.7 %)

22 (14.7 %)ǂ

 Anti-diabetic treatment

  Insulin

NA

20 (13.3 %)

NA

22 (14.7 %)

  Sulfonylureas

NA

61 (40.7 %)

NA

32 (21.3 %)

  Metformin

NA

94 (62.7 %)

NA

62 (41.3 %)

  α glycosidase inhibitors

NA

70 (46.7 %)

NA

42 (28.0 %)

Mean (SD)

 Age (years)

52.9 (8.2)

56.6 (6.0)§

53.8 (8.3)

54.5 (10.9)

 Body mass index (kg/m2)

26.2 (3.9)

26.4 (4.0)

25.2 (4.1)

26.5 (3.4)Å‚

 Systolic pressure (mm Hg)

131.8 (20.8)

138.8 (17.8)Å‚

133.8 (18.9)

135.2 (19.8)

 Diastolic pressure (mm Hg)

76.8 (10.6)

77.1 (11.2)

78.9 (12.1)

82.7 (10.8)Ç‚

 eGFR (ml/min/1.73 m2)

131.4 (28.6)

116.8 (32.9)§

118.1 (28.3)

105.6 (42.5)Å‚

 Total cholesterol (mg/dL)

195.9 (35.4)

195.1 (35.8)

187.0 (29.3)

176.8 (40.0)*

 LDL cholesterol (mg/dL)

118.3 (35.7)

121.4 (32.2)

111.3 (24.8)

108.5 (34.0)

 HDL cholesterol (mg/dL)

54.6 (12.8)

49.8 (9.7)Ç‚

52.9 (13.8)

43.8 (13.9)§

 Fasting blood glucose (mmol/L)

5.0 (0.4)

8.3 (2.4)§

5.1 (1.5)

8.9 (2.8)§

Geometric mean (IQR)

 Triglyceride (mg/dL)

111.5 (81.4–176.1)

123.7 (117.8–129.8)

106.0 (100.3–112.0)

150.8 (140.4–161.9)§

 Insulin (pmol/L)

50.9 (37.2–71.4)

58.9 (56.2–63.1)*

38.5 (36.4–40.7)

33.6 (30.3–37.2)

 Homa-β

92.0 (76.2–110.8)

41.7 (38.9–43.7)§

75.5 (71.9–79.4)

24.1 (22.0–26.4)§

 Homa-IR

0.97 (0.69–1.32)

1.25 (0.80–1.91)§

0.77 (0.47–1.14)

0.78 (0.29–1.50)

  1. eGFR estimated glomerular filtration rate; ACE inhibitors Angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blocker; LDL low-density lipoprotein; HDL high-density lipoprotein; Homa-βand Homa-IR were computed by Homeostasis Model Assessment algorithm (http://www.dtu.ox.ac.uk/homacalculator/) using fasting insulin and fasting blood glucose; IQR interquartile range
  2. * p ≤ 0.05; ł p ≤ 0.01; ǂ p ≤ 0.001; and § p ≤ 0.0001 when compared with sex-matched controls
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840